General Information
Drug ID
DR00391
Drug Name
Cerivastatin
Drug Type
Small molecular drug
Indication Hyperlipidaemia [ICD11: 5C8Z] Approved [1]
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=446156"></iframe>
3D MOL 2D MOL
Formula
C26H34FNO5
Canonical SMILES
CC(C)C1=C(C(=C(C(=N1)C(C)C)C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)COC
InChI
InChI=1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1
InChIKey
SEERZIQQUAZTOL-ANMDKAQQSA-N
CAS Number
CAS 145599-86-6
Pharmaceutical Properties Molecular Weight 459.558 Topological Polar Surface Area 99.9
Heavy Atom Count 33 Rotatable Bond Count 11
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 7
PubChem CID
446156
PubChem SID
10167 , 10299839 , 103541455 , 104635877 , 10852026 , 126681828 , 134339434 , 134339836 , 135259857 , 135650063 , 137002687 , 142742086 , 14809054 , 14858094 , 160963785 , 164788182 , 164807583 , 176484089 , 179116613 , 184546299 , 198953954 , 223659548 , 223898596 , 226406536 , 226406537 , 241035409 , 252347182 , 36888654 , 46505877 , 46518451 , 48415746 , 50067077 , 50070698 , 50728881 , 51091965 , 56312092 , 56313141 , 56313595 , 7978896 , 822164 , 92308707 , 93166525 , 93578306
ChEBI ID
CHEBI:3558
TTD Drug ID
D03KIA
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [3]
NTCP Transporter Info Sodium/taurocholate cotransporting polypeptide Substrate [4]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [5]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [5]
OATP2B1 Transporter Info Organic anion transporting polypeptide 2B1 Substrate [6]
P-GP Transporter Info P-glycoprotein 1 Substrate [3]
References
1 Cerivastatin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
3 Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67.
4 Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica. 2011 Jan;41(1):24-34.
5 FDA Drug Development and Drug Interactions
6 pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011 Aug 1;8(4):1303-13.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.